Navigation Links
Insmed Initiates Clinical Study for Follow-on Biologic Version of Neulasta(R)
Date:10/14/2008

his FOB trial is the second of two planned for 2008 as part of Insmed's development of a portfolio of FOBs. In July 2008, the Company announced that a completed Phase I clinical trial had demonstrated the bioequivalence of INS-19, the Company's recombinant human granulocyte colony stimulating factor (G-CSF), compared to Neupogen(R), an FDA-approved G-CSF product for the treatment of neutropenia that recorded 2007 sales of approximately $1 billion. Insmed intends to seek approval of INS-19 and INS-20 in the U.S. and launch the products on expiration of the relevant innovator patents, which is in 2013 for Neupogen(R) and 2015 for Neulasta(R).

The Follow-on Biologics Market

According to published reports, an estimated $10 billion worth of biologic drugs are expected to come off patent by 2010, with an additional $10 billion by 2015. FOBs would provide safe and effective therapies at a reduced cost following the expiration of the original product's patent. A recent econometric study by economist Dr. Robert J. Shapiro, former Under Secretary of Commerce in the Clinton Administration, found that "...generic versions of the top 12 categories of biologic treatments with patent protections that have expired or that are due to expire in the near future could save Americans $67 billion to $108 billion over 10 years and $236 billion to $378 billion over 20 years."

About INS-20

Pegylated recombinant human G-CSF is a chemically modified version of G-CSF in which a water soluble polymer called polyethylene glycol is attached to the protein. The pegylated protein has a prolonged biological activity after it is injected into the patient. This allows less frequent dosing for the patient compared to recombinant human G-CSF. The FDA approved version of this drug is Neulasta(R). INS-20 is Insmed's follow-on biologic version of Neulasta(R).

About Insmed

Insmed Inc. is a biopharmaceutical company with unique protein process development and manuf
'/>"/>

SOURCE Insmed Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Insmed CEO to Present at Congressional Briefing on Follow-On Biologics
2. Insmed Announces First Human Bioequivalence Data for a Follow-on Biologic by a U.S. Company
3. Insmed Provides Update on Follow-On Biologics and IPLEX(TM) Programs
4. Insmed Initiates Clinical Study for Follow-on Biologic Version of Neupogen(R)
5. Insmed Launches National Awareness Campaign Surrounding Follow-On Biologics
6. Insmed Provides Update on IPLEX(TM) Expanded Access Program in Italy for the Treatment of Amyotrophic Lateral Sclerosis
7. Insmed Receives FDA Orphan Drug Designation for IPLEX(TM) in the Treatment of Myotonic Muscular Dystrophy
8. Circassia Initiates Further Phase II Clinical Study of Toleromune(R) Anti-Allergy Technology
9. Baxter Initiates Phase III Trial for the Treatment of Alzheimers Disease
10. S*BIO Initiates U.S. Phase I Clinical Trials of Oral JAK2 Inhibitor SB1518 for the Treatment of Hematological Malignancies
11. Enanta Initiates Phase 1 Study on EDP-322, an Oral Antibiotic With Activity Against Hospital- and Community-Acquired MRSA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... , Aug. 21, 2014 The spinal column ... the human body. Signals carried to and from the brain ... skills and nervous system. Injury or ailment here can be ... with a loss of control over their body. Though back ... a person,s life, there are more options available to make ...
(Date:8/21/2014)... Aug. 21, 2014 /CNW/ - Eisai Limited is pleased to ... the first-of-its-kind comic book available in Canada ... designed specifically to educate children and their parents about epilepsy, ... affecting more than 300,000 Canadians. Eisai is guided by ... , in which the patient is central – there was ...
(Date:8/21/2014)... Mass. , Aug. 21, 2014  Decision ... COPD,  physicians in Brazil ... follow clinical guidelines and commonly prescribe long-acting beta-agonist ... although they do so within current severe cost/coverage ... (FDCs) that are expected to launch in these ...
Breaking Medicine Technology:Don't Live in Pain: Four Life Improving Benefits of Back Surgery 2Eisai Pleased to Support Canadian Epilepsy Alliance Comic Book that Teaches Children About Epilepsy 2Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 2Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 3
... Food and Drug Administration (FDA) approves many generic drugs that treat a wide variety of ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO ) ... This FDA Consumer Update describes seven significant approvals made by ... , , ...
... to gain acceptance.  Additional financing will allow the Talheim ( Germany ) based company to accelerate the development of new products. , ... , , ... ... ...
Cached Medicine Technology:FDA Consumer Health Information - Generic Drug Roundup: April 2010 2Novalung Records 50% Growth 2Novalung Records 50% Growth 3
(Date:8/23/2014)... Pittsburgh, PA (PRWEB) August 23, 2014 ... penis sometimes comes into contact with the dirty water ... or the seat itself," said one of two inventors ... exposure to germs, we developed this protective device." , ... contacting unsanitary toilet surfaces, including the water, bowl and ...
(Date:8/23/2014)... 2014 On Monday, August 18th, ... breach suffered by Community Health Systems, which operates ... 4.5 million records containing Personally Identifiable Information (PII) like ... Mandiant, who was engaged to investigate the incident, the ... group of cyber attackers based in China, who they ...
(Date:8/23/2014)... 2014 Pixel Film Studios, a leader of ... release of ProIntro Vol.3, a customizable title tool for ... tile just by dragging ProIntro Vol.3 in their timeline" says ... a definite time saver and i think our users will ... beautifully designed titles made with Final Cut Pro X users ...
(Date:8/23/2014)... (PRWEB) August 23, 2014 Teen drug ... Carolina. It’s no different in Wilmington, NC. Substance abuse ... are falling victim to drug and alcohol dependency in ... are looking to overcome substance abuse, but don’t know ... adolescent treatment facility can be a challenge because most ...
(Date:8/22/2014)... The IT manager of Top10BestSEOHosting.com is a web professional ... has recently announced that GoDaddy ( http://www.top10bestseohosting.com/go/GoDaddy.com/ ) is ... GoDaddy is a popular supplier of cheap web hosting, ... at affordable rates. It offers three Linux shared hosting ... on the length of the contract. The longest contract ...
Breaking Medicine News(10 mins):Health News:This Time Prominent Hospital Group Falls Prey to Hackers Believed to be Based in China 2Health News:This Time Prominent Hospital Group Falls Prey to Hackers Believed to be Based in China 3Health News:This Time Prominent Hospital Group Falls Prey to Hackers Believed to be Based in China 4Health News:A new plugin was announced today, ProIntro Vol.3 from Pixel Film Studios for Final Cut Pro X 2Health News:Troubled Teens Wilmington Helpline Guides Adolescents to the Path of Recovery 2
... 20, 2009 Researchers at Ben-Gurion University of the Negev ... and terrorist attacks in adolescents, demonstrating that strong social support ... The study, believed to be the first of its ... , the journal of The American Academy of Pediatrics. ...
... , , , WASHINGTON, July 20 The ... , Pro-life leaders to hold press conference discussing potential backlash -- ... to kill the innocent. , , Address: National Press ... Time and Date: 2:00 PM, Tuesday, July 21 , , ...
... looks at costs and benefits of revising treatment guidelines ... therapy soon after an HIV diagnosis should be standard ... cost is a barrier, new research contends. , An ... avoided over a five-year period, the researchers say, if ...
... , CHAPEL HILL, N.C., July 20 RealMed ... partnership to provide RealMed EDI Revenue Management Services to clients ... RealMed will provide services including online ECS claims filing, editing ... Eligibility Verification). In return, TSI Healthcare has committed ...
... , WESTBURY, N.Y., July 20 ... Long Island (OCLI) practice will perform FREE surgery at the Island ... have lost some or all of their vision because of cataracts. ... this outpatient surgical procedure to residents of Nassau, Suffolk and Queens ...
... , , ... , MADISON, N.J., July 20 ... (NYSE: DGX ), today announced that NYCLIX is ... organizations across New York City using the company,s Centergy(TM) ...
Cached Medicine News:Health News:Social support buffers adolescent depression after terrorist attacks: Ben-Gurion University 2Health News:Earlier HIV Treatment Could Save Lives Worldwide 2Health News:RealMed Corporation and TSI Healthcare Announce Strategic Partnership 2Health News:Ophthalmic Consultants of Long Island (OCLI), the Largest and One of the Most Prestigious Multi-Specialty Ophthalmology Practices on Long Island, Participates in Mission Cataract USA 2Health News:Ophthalmic Consultants of Long Island (OCLI), the Largest and One of the Most Prestigious Multi-Specialty Ophthalmology Practices on Long Island, Participates in Mission Cataract USA 3Health News:Quest Diagnostics MedPlus Subsidiary Enables New York Clinical Information Exchange (NYCLIX) to Share Meaningful Data and Enhance Patient Care 2Health News:Quest Diagnostics MedPlus Subsidiary Enables New York Clinical Information Exchange (NYCLIX) to Share Meaningful Data and Enhance Patient Care 3Health News:Quest Diagnostics MedPlus Subsidiary Enables New York Clinical Information Exchange (NYCLIX) to Share Meaningful Data and Enhance Patient Care 4
CK-MB Control...
For the quantitative in vitro determination of CK-MB in serum and plasma...
For the quantitative in vitro determination of Cholesterol in serum and plasma....
For the quantitative in vitro determination of Alkaline Phosphatase in serum or plasma....
Medicine Products: